Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232881 · ClinicalTrials.gov registry record
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
A clinical trial, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- 27
- Enrollment target
NCT01232881 is a clinical trial that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 27 participants.
The verdict
NCT01232881 was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Interventions
- PROCEDURE Tumor Sample
- PROCEDURE Serum Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232881
The ClinicalTrials.gov registry entry for NCT01232881 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tumor Sample is the first listed.
NCT01232881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232881 about?
NCT01232881 is a clinical study titled "Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer". This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
What is the current status of trial NCT01232881?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2009-08. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01232881?
The interventions under investigation include: Tumor Sample (PROCEDURE), Serum Sample (PROCEDURE).
Who is sponsoring clinical trial NCT01232881?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.